Piper Jaffray Companies Comments on Audentes Therapeutics Inc’s Q1 2021 Earnings (NASDAQ:BOLD)

Audentes Therapeutics Inc (NASDAQ:BOLD) – Equities researchers at Piper Jaffray Companies issued their Q1 2021 earnings per share (EPS) estimates for shares of Audentes Therapeutics in a report released on Thursday, November 7th. Piper Jaffray Companies analyst C. Raymond anticipates that the biotechnology company will post earnings per share of ($1.07) for the quarter. Piper Jaffray Companies also issued estimates for Audentes Therapeutics’ Q2 2021 earnings at ($1.01) EPS and Q3 2021 earnings at ($0.61) EPS.

Several other equities analysts also recently weighed in on the company. ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Robert W. Baird started coverage on Audentes Therapeutics in a research report on Wednesday, October 2nd. They issued an “underperform” rating and a $10.00 target price on the stock. Mizuho restated a “buy” rating and issued a $45.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. Evercore ISI restated a “hold” rating and issued a $34.00 target price on shares of Audentes Therapeutics in a research report on Monday. Finally, Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $40.28.

Shares of NASDAQ BOLD traded down $1.18 during midday trading on Monday, hitting $27.39. The stock had a trading volume of 9,741 shares, compared to its average volume of 490,503. The company has a market capitalization of $1.24 billion, a PE ratio of -8.06 and a beta of 1.77. The stock has a 50 day simple moving average of $28.15 and a 200-day simple moving average of $34.34. Audentes Therapeutics has a 1 year low of $17.95 and a 1 year high of $41.65.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same period in the previous year, the company posted ($0.97) earnings per share.

In related news, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 5.30% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. lifted its holdings in Audentes Therapeutics by 578.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at about $46,000. Tower Research Capital LLC TRC lifted its holdings in shares of Audentes Therapeutics by 1,137.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 2,241 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Audentes Therapeutics by 50.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock valued at $113,000 after purchasing an additional 1,005 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Audentes Therapeutics by 810.4% in the 2nd quarter. Bank of Montreal Can now owns 4,106 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 3,655 shares during the last quarter. Hedge funds and other institutional investors own 98.44% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: What moving averages are used to define a golden cross?

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.